Data regarding involvement of POT1 and DCLRE1B genes in telomeropathies are only recently emerging with proposals that these genes should be included on cancer‐risk predisposing multigene panel tests as well as genetic tests for telomere biology dysfunction [10, 11]. This evidence concerns the gene POT1 and cancer.